Poolbeg Pharma (POLB) |

Poolbeg Pharma #POLB – POLB 001 US Patent update

4 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property (IP) position around POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The US Patent […]

Alan Green covers Poolbeg Pharma #POLB & Sovereign Metals #SVML on this week’s Stockbox Research Talks

Poolbeg Pharma #POLB licence of Melioidosis vaccine candidate

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that further to the Option Agreement announced in December 2021, Poolbeg has signed an exclusive Licence Agreement with University College Dublin (UCD) through NovaUCD, the University’s knowledge transfer office, for […]

#POLB Poolbeg Pharma PLC – HC Wainwright Global Investment Conference

12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in […]

Poolbeg Pharma #POLB – Interim results for the six months to 30 June 2022

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022. Financial & Operational Highlights • Well capitalised with a strong cash balance of £18.9m as at 30 June […]

Alan Green discusses #WTB Whitbread, #POLB Poolbeg Pharma & #FCM First Class Metals on the Vox Market Podcast

Alan Green discusses #WTB Whitbread, #POLB Poolbeg Pharma & #FCM First Class Metals on the Vox Market Podcast Listen here

A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington

A landmark year for Poolbeg Pharma #POLB – Alan Green talks to CEO Jeremy Skillington, who takes us through what has been a very eventful year since the IPO. At 01:58 we discuss the flagship asset POLB 001, which reached a major milestone last week as it commenced a human challenge trial. At 05:00 Jeremy provides […]

UK Investor Magazine Podcast – Covering Royal Mail #RMG Poolbeg Pharma #POLB & GreenX Metals #GRX

Alan Green joins the Podcast for an in-depth discussion around the current market conditions and a selection of UK equities. We break down the current market dynamics and question whether we have seen a bottom in markets as investor sentiment improves. Royal Mail has changed their name after a torrid period of trading and a […]

Poolbeg Pharma #POLB – Major milestone reached as POLB 001 human challenge clinical trial ready to commence

20 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims […]

News Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

Poolbeg featured in the @MorningstarInc following yesterdays announcement on the completion of build 7 optimisation of our #AI model for RSV #data, the first time AI used to model #RSV with complete longitudinal #disease data. Link below to read in full: https://www.morningstar.co.uk/uk/news/AN_1656323268845373200/poolbeg-pharma-ai-model-of-respiratory-syncytial-virus-starts-analysis.aspx